Biosimilars are becoming more common as more launch on the market in the United States, but patient and provider education can help speed uptake of these products, explained Bincy Abraham, MD, Houston Methodist – Weill Cornell.
Want to read the full conversation? Check out the Q&A.
As more biosimilars become available, it is still important to educate patients and providers that the safety and efficacy of these products is equivalent to the originator product. This education is one way to improve uptake of biosimilars and prevent delays in care when payers prefer a biosimilar and patients need to switch products, explained Bincy Abraham, MD, professor of clinical medicine, distinguished professor, director of the Fondren Inflammatory Bowel Disease Program, and director of the gastroenterology and hepatology fellowship at Houston Methodist – Weill Cornell.
Since payers control what products are on formulary, the provider role in increasing uptake is mostly around educating other providers on the safety and efficacy of biosimilars so providers are more comfortable prescribing biosimilars and talking to their patients about switching to biosimilars, she said.
Sometimes there are patients who are adamant about staying on the reference product, and when this happens, the provider’s role is to understand what is driving that preference and address any patient concerns. For instance, if the patient is concerned about their disease flaring when they switch, the provider can explain the results of switching studies of similar patients who were on the reference product and switched to a biosimilar.
In addition, she noted that disease flare might actually happen if the patient requires the provider negotiate with insurers for the patient to stay on the reference product. This delay in care could increase the risk of their disease worsening. Finally, patients may not realize that switching to the biosimilar will be the same cost or cheaper than staying on the reference product.
Finally, when faced with payer preferences for certain biosimilars, Abraham and her team will choose a biosimilar that is likely to get the fastest approval for the patient, perhaps because the office staff are familiar with the approval process and the representative on the other end, which will make the process of getting an approval faster.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
A new federal rule will enable thousands of immigrants in the Deferred Action for Childhood Arrivals (DACA) program to obtain health care through the Affordable Care Act; a forthcoming CMS rule is expected to lower home-based care wait times and raise caregiver wages; the HHS Office for Civil Rights has finalized 2 rules that strengthen the ACA’s health care discrimination ban.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More